Ascendis Pharma AS (ASND):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Ascendis Pharma AS (ASND) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8051
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:49
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:デンマーク
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Ascendis Pharma A/S (Ascendis) is a biopharmaceutical company that offers drug discovery and development services. The company’s pipeline products include transcon growth hormone, transcon PTH, transcon CNP, and transcon peptides. Ascendis conducts research and develops new drug candidates for treatment. The company’s products are used in the therapeutic areas of diabetes, growth hormone deficiency, endocrinology, and others. It partners with pharmaceutical and biotechnology companies to develop new products. The company has its operations in the US, Germany and Denmark. Ascendis is headquartered in Hellerup, Denmark.

Ascendis Pharma AS (ASND) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Ascendis Pharma A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Ascendis Pharma A/S, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Ascendis Pharma A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Ascendis Pharma A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Ascendis Pharma A/S, Medical Devices Deals, 2012 to YTD 2018 10
Ascendis Pharma A/S, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Ascendis Pharma A/S, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Ascendis Pharma Raises USD60 Million in Series D Venture Financing 12
Partnerships 14
Ascendis Pharma Enters Into Collaboration Agreement with Genentech 14
Equity Offering 15
Ascendis Pharma Raises USD258.7 Million in Public Offering of American Depositary Shares 15
Ascendis Pharma Prices Public Offering of American Depositary Shares for USD135 Million 17
Ascendis Pharma Raises USD120 Million in Public Offering of ADS 19
Ascendis Pharma Raises USD124 Million in IPO 21
Ascendis Pharma A/S – Key Competitors 23
Ascendis Pharma A/S – Key Employees 24
Ascendis Pharma A/S – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
Aug 29, 2018: Ascendis pharma announces second quarter 2018 financial results 26
May 30, 2018: Ascendis Pharma Announces First Quarter 2018 Financial Results 27
Mar 28, 2018: Ascendis Pharma Announces Full Year 2017 Financial Results 28
Nov 16, 2017: Ascendis Pharma Reports Third Quarter 2017 Financial Results 29
Aug 18, 2017: Ascendis Pharma Reports Second Quarter 2017 Financial Results 30
May 23, 2017: Ascendis Pharma Reports First Quarter 2017 Financial Results 31
Mar 22, 2017: Ascendis Pharma Reports Full Year 2016 Financial Results 32
Corporate Communications 33
Apr 02, 2018: Ascendis Pharma Appoints Thomas A. Larson as Chief Commercial Officer 33
Product News 34
09/05/2017: Ascendis Pharma Announces Presentations on TransCon CNP at Upcoming Medical Conferences 34
09/05/2017: Ascendis Pharma Announces Presentations on TransCon PTH at Upcoming Medical Conferences 35
03/19/2018: Ascendis Pharma Announces Poster on TransCon Growth Hormone at ENDO 2018 36
02/28/2017: Ascendis Pharma Announces Data on TransCon CNP at ENDO 2017 37
02/28/2017: Ascendis Pharma Announces Data on TransCon PTH at ENDO 2017 38
Clinical Trials 39
May 08, 2018: Ascendis Pharma Announces Dosing of First Subjects in Phase 1 Trial of TransCon CNP 39
Jan 08, 2018: Ascendis Pharma Provides Update on TransCon CNP 40
Jan 08, 2018: Ascendis Pharma Provides Update on TransCon Growth Hormone 41
Jan 03, 2018: Ascendis Pharma Announces Completion of Target Enrollment in Phase 3 Trial of TransCon Growth Hormone for Pediatric Growth Hormone Deficiency 42
Sep 26, 2017: Ascendis Pharma Announces Dosing of Subjects in Phase 1 Trial of TransCon PTH 43
Apr 03, 2017: Ascendis Pharma Presents Data on TransCon CNP at ENDO 2017 44
Apr 03, 2017: Ascendis Pharma Presents Data on TransCon PTH at ENDO 2017 45
Apr 03, 2017: Ascendis Pharma Showcases New Data on Rare Disease Product Pipeline at ENDO 2017 46
Feb 28, 2017: Ascendis Pharma Announces Data on TransCon Growth Hormone at ENDO 2017 47
Feb 16, 2017: Ascendis Pharma Announces Publication of Comprehensive Results from Randomized, Active-Controlled Phase 2 Trial of Once-Weekly TransCon Growth Hormone in Pediatric Patients 48
Appendix 49
Methodology 49
About GlobalData 49
Contact Us 49
Disclaimer 49

List of Tables
Ascendis Pharma A/S, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Ascendis Pharma A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Ascendis Pharma A/S, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Ascendis Pharma A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Ascendis Pharma A/S, Deals By Therapy Area, 2012 to YTD 2018 9
Ascendis Pharma A/S, Medical Devices Deals, 2012 to YTD 2018 10
Ascendis Pharma A/S, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Ascendis Pharma Raises USD60 Million in Series D Venture Financing 12
Ascendis Pharma Enters Into Collaboration Agreement with Genentech 14
Ascendis Pharma Raises USD258.7 Million in Public Offering of American Depositary Shares 15
Ascendis Pharma Prices Public Offering of American Depositary Shares for USD135 Million 17
Ascendis Pharma Raises USD120 Million in Public Offering of ADS 19
Ascendis Pharma Raises USD124 Million in IPO 21
Ascendis Pharma A/S, Key Competitors 23
Ascendis Pharma A/S, Key Employees 24
Ascendis Pharma A/S, Subsidiaries 25

List of Figures
Ascendis Pharma A/S, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Ascendis Pharma A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Ascendis Pharma A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Ascendis Pharma A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Ascendis Pharma A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Ascendis Pharma A/S, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Ascendis Pharma A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Ascendis Pharma A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Ascendis Pharma A/S, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Ascendis Pharma AS (ASND):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Kadimastem Ltd (KDST):製薬・医療:M&Aディール及び事業提携情報
    Summary Kadimastem Ltd (Kadimastem) is a clinical stage biopharmaceutical company that develops industrial regenerative medicines to treat neuro-degenerative diseases. Its technology platform enables the manufacturing of islet-like endocrine cells (differentiated cells) and glia restricted progenito …
  • Stereotaxis Inc (STXS):製薬・医療:M&Aディール及び事業提携情報
    Summary Stereotaxis Inc (Stereotaxis) designs, manufactures and markets robotic systems and instruments for electrophysiologists for the treatment of cardiac arrhythmias. Its flagship product, Epoch solution is an advanced remote robotic navigation system for use in interventional lab for the treatm …
  • A. O. Smith Corporation (AOS):企業の財務・戦略的SWOT分析
    A. O. Smith Corporation (AOS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Global Ports Holding PLC (GPH):企業の財務・戦略的SWOT分析
    Global Ports Holding PLC (GPH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Qiagen NV (QIA)-製薬・医療分野:企業M&A・提携分析
    Summary Qiagen NV (Qiagen) is a provider of molecular testing solutions. Its solutions include sample and assay technologies, bioinformatics and automation systems. Qiagen’s sample technologies help isolate and process DNA, RNA and proteins from samples such as blood and tissue. The company’s produc …
  • Acino International AG:製薬・医療:M&Aディール及び事業提携情報
    Summary Acino International AG (Acino), formerly Acino Holding AG, manufactures and commercializes generic and prescription pharmaceuticals in novel drug delivery forms. The company focuses on the therapeutic areas of oncology, cardiology and metabolism, central nervous system, gastroenterology, inf …
  • TOTAL S.A.:戦略・SWOT・企業財務分析
    TOTAL S.A. - Strategy, SWOT and Corporate Finance Report Summary TOTAL S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Applied DNA Sciences Inc (APDN):企業の財務・戦略的SWOT分析
    Summary Applied DNA Sciences Inc (APDN) is a biotechnology company that provides DNA based security and authentication solutions and services. The company offers products such as DNA security tools, DNA marking kit for assets and valuables, test kits, intruder and offender tagging systems; custom DN …
  • Option NV (OPTI):企業の財務・戦略的SWOT分析
    Option NV (OPTI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Cheung Kong Infrastructure Holdings Ltd:戦略・SWOT・企業財務分析
    Cheung Kong Infrastructure Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Cheung Kong Infrastructure Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Aerocon Engineering Company:企業の戦略・SWOT・財務情報
    Aerocon Engineering Company - Strategy, SWOT and Corporate Finance Report Summary Aerocon Engineering Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • The Dixie Group Inc:企業の戦略・SWOT・財務情報
    The Dixie Group Inc - Strategy, SWOT and Corporate Finance Report Summary The Dixie Group Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • RayBiotech Inc-製薬・医療分野:企業M&A・提携分析
    Summary RayBiotech Inc (RayBiotech) is a life science company that offers proteins, antibodies and immunological kits. The company’s products include antibody arrays, elisa, functional assays, antibodies and custom recombinant protein service. It provides services such as testing services, custom se …
  • SoftBank Group Corporation:企業のM&A・事業提携・投資動向
    SoftBank Group Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's SoftBank Group Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • Moravske naftove doly AS:企業の戦略的SWOT分析
    Moravske naftove doly AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • BDO International Limited:戦略・SWOT・企業財務分析
    BDO International Limited - Strategy, SWOT and Corporate Finance Report Summary BDO International Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • DFDS AS (DFDS):企業の財務・戦略的SWOT分析
    DFDS AS (DFDS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Samba Private Banking:企業の戦略・SWOT・財務情報
    Samba Private Banking - Strategy, SWOT and Corporate Finance Report Summary Samba Private Banking - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • OZ Minerals Ltd:企業の戦略・SWOT・財務情報
    OZ Minerals Ltd - Strategy, SWOT and Corporate Finance Report Summary OZ Minerals Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • SPI Energy Co Ltd (SPI)-エネルギー分野:企業M&A・提携分析
    Summary SPI Energy Co Ltd (SPI Energy), formerly Solar Power Inc, is a renewable energy company that offers photovoltaic solutions. The company operates in development, financing, installation, operation and sale of utility-scale and residential solar power projects in China. It also operates online …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆